PD-1 knockout engineered T cells - Anhui Kedgene Biotechnology

Drug Profile

PD-1 knockout engineered T cells - Anhui Kedgene Biotechnology

Latest Information Update: 01 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Anhui Kedgene Biotechnology
  • Developer Anhui Kedgene Biotechnology; Hangzhou Cancer Hospital
  • Class Antineoplastics; Cell therapies; Gene therapies; T lymphocyte cell therapies
  • Mechanism of Action Gene transference; PDCD 1 protein inhibitors; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Oesophageal cancer

Most Recent Events

  • 20 Mar 2017 Phase-II clinical trials in Oesophageal cancer (Metastatic disease, Second-line therapy or greater, Recurrent, Late-stage disease) in China (IV, Infusion) (NCT03081715)
  • 11 Mar 2017 Anhui Kedgene Biotechnology plans a phase II trial for Oesophageal cancer in China (NCT03081715)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top